MedTrace Logo

Pancreatic Cancer Detection Consortium

NCT06388967 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-12-19

No results posted yet for this study

Summary

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Conditions

  • Pancreatic Cancer
  • Pancreatic Carcinoma
  • Pancreatic Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Neoplasms
  • Pancreatic Cancer Stage I
  • Pancreatic Cancer Stage
  • Pancreatic Cancer Resectable
  • Pancreatic Cancer Stage 0
  • Pancreatic Cancer Stage II
  • Pancreatic Cancer Stage III
  • Pancreatic Cancer, Adult
  • Pancreatic Cancer Non-resectable

Interventions

DIAGNOSTIC_TEST

PANcreatic cancer Exosome Early detectiON (PANXEON)

This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Ajay Goel, PhD · City of Hope Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2026-06-18
Completion
2026-06-18

Countries

  • United States
  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06388967 on ClinicalTrials.gov